

The Florida Cancer Data System's Memo

April 2023

Florida Cancer Data System



University of Miami Miller
School of Medicine
Fox Building - Room 410
1550 NW 10th Ave
Miami, Florida 33136
or
PO Box 016967 (D4-11)
Miami, Florida 33101

Phone: (305) 243-4600
Fax: (305) 243-4871

Data Acquisition Manual 2023



WHAT'S NEW:

*The following information
is currently available on the
FCDS website.*

**WEIGHT-RELATED
CANCERS IN FLORIDA
1992-2013 MONOGRAPHS**

**FCDS RESEARCH
JOURNAL PUBLICATIONS
REPORT**

**FCDS/NAACCR
EDIT's Metafile
V22b Metafile,
posted on 8/2/2022**

**FCDS/NAACCR
WEBINAR SERIES:
NAACCR 2022-2023
Cancer Registry and Surveillance
Webinar Series 5/4/2023-
Lower GI 2023 Part 1***
In person attendance cancelled until
further notice. Please Login to
FCDS IDEA->Education->FLccSC
Learning Management 2 weeks
after webinar to watch recordings
and get CEUs *****

FCDS Florida Cancer Data System

**Florida Statewide Cancer
Registry**



Florida Cancer Data System Deadlines, Updates, & Reminders



The 2023 FCDS DAM is NOW AVAILABLE on FCDS Website

2023 will be another year of significant changes to National Cancer Reporting Requirements. FCDS continues to require only those data items consistent with the CDC NPCR Requirements plus a few additional Florida-Specific Data Items such as ‘Historical Cancers’. FCDS continues to require a subset of the CoC Requirements. FCDS IDEA Single Entry will be updated on July 1, 2023 to meet v23 standards.

Vendors have had the FCDS requirements since October 2022. So you should have no problem with delays in receipt of your v23 software. There will likely be an updated FCDSv23 EDITS Metafile posted in June 2023. But that is the only anticipated update to the FCDS Requirements posted last year.

Changes are highlighted in red as they were last year. This seems to have been a welcome change when we introduced it last year. There is also a Summary of Changes in Appendix S. And, a few important updates from last year continue to be highlighted in red to make them easy to spot in the manual.

The 2023 Resources for Registrars has been updated with all of the new links for updated manuals, etc.

The CoC has introduced a new data item ‘Surgery of Primary Site (2023)’ to be used for cases diagnosed 1/1/2023 and later. This new 4-character field is a work-in-progress. The new format is explained in the FCDS DAM and in the STORE Manual. It may take more than a year to get all site-specific surgery codes updated into the new coding system. There is no crosswalk planned to map the old codes to the new.

So, we now have 2 sets of Surgery of Primary Site Codes – codes for cases diagnosed 1981-2022 and a completely different set of Surgery of Primary Site Codes for cases diagnosed 1/1/2023 and later.

FCDS will be requiring only 2 new SSDIs in 2023. One is not really a new SSDI. It is just a new cancer site added to the existing SSDI ‘p16’. Anus has been added to data item 3956 – SSDI p16. The other new SSDI is only for appendix. It is called ‘Histologic Subtype’ and it is used to differentiate between different histologic subtypes of mucinous adenocarcinoma in the appendix; low-grade appendiceal neoplasm (LAMN), high-grade appendiceal neoplasm (HAMN), and mucinous adenocarcinoma. All of these neoplasms use the same 4-digit histology code (8480). However, they each behave differently.

The Casefinding Section and Appendix has been updated for 2023 patient encounters. A copy of the ‘short-list’ is included in this FCDS Memo. The ‘long-list’ includes every ICD-10-CM Diagnosis Code that MUST at a minimum be included in your medical record disease index casefinding. And, just a reminder that medical record casefinding should NEVER be your ONLY casefinding source.

(Continued on page 3)



Florida Cancer Data System Deadlines, Updates, & Reminders

(Continued from page 2)

Registrars should perform complete casefinding in pathology, in-patient and ambulatory patient care services, oncology and disease specialty clinics, diagnostic imaging, and any other patient services that may diagnose or treat cancers. Registrars WILL MISS CASES when you do not include all services including all pathology.

FCDS has included details for 2021, 2022 and 2023 New Reportable Neoplasms to make it easier to locate the new terms, histology codes, and conditions that are newly reportable or deemed not reportable during these 3 years. It has become increasingly difficult to weed through all of the various manuals to be sure you locate all of the new cancer types and subtypes as many do not sound like cancer...and some registrars forget to update the Casefinding Search Criteria with IT Services each year.

Finally, there is a new addition to Appendix C – glossary – which explains the difference between ‘Active Surveillance’ and ‘Watchful Waiting’. Many registrars think they are the same thing...they are not. But both use the same Treatment Status Code = 2. Please take a moment to review all changes for 2023.



REMINDER of MONTHLY DEADLINE for CORRECTIONS/INQUIRIES

FCDS knows that EVERYBODY is super busy these days. We also know that for some of us little things like Submission Corrections/Inquiries and QC Review Corrections/Inquiries rank pretty far down on our work priorities list. However, FCDS wants to remind our registrars that it is FCDS Policy (loosely enforced) that each Facility return BOTH Submission Corrections and QC Corrections and any Inquiries within one (yes ‘1’) month after you receive them. This is the same for small and large facilities.

The 2023 FCDS DAM states the Deadline for sending back Corrections to FCDS (Any Corrections or Inquiries) is 1 month after you receive them. This is spelled out in both Section I and in the FCDS Calendar and FCDS Recurring Deadlines. Cases held in the pending queue of corrections/inquiries are not available as ‘finalized’ cases until they have been resolved. They are not yet complete or counted.

(Continued on page 4)



Florida Cancer Data System Deadlines, Updates, & Reminders

(Continued from page 3)

Some registrars wait a whole year to even look at their Corrections or QC. That just isn't acceptable. Remember, there was a time when FCDS would not allow you to submit a new batch until/unless your Submission Corrections were at or near ZERO. We would just reject any submissions. Nobody wants those days to return...it was bad for all of us.

FCDS is considering adding a review of how well facilities adhere to not only our quarterly and annual deadlines, but also adherence to FCDS monthly correction/inquiry policies to the FCDS Jean Byers and FCDS Pat Strait Awards as a criterion when FCDS is reviewing Facilities in consideration of the awards.

So please remember to keep up with your Submissions Corrections and Inquiries as well as your QC Review Corrections and Inquiries on a 'monthly' basis or you will fall further and further behind.

Another advantage to keeping up with these inquiries and corrections is that they are intended to identify poor abstracting and/or documentation patterns, poor coding patterns, and to give you feedback on the quality of your data on an ongoing basis. EDITS are not your only criteria for 'good' abstracting. Strong text that backs up good coding and an abstract that 'tells a story' and 'makes sense' are all signs of strong abstracting skills. Meeting Deadlines is just good data operations management.

Thank you for all you do to support FCDS. Corrections, questions and clarifications are just a small part of the vast array of job tasks we perform routinely as cancer registrars. Thank you for being timely and complete and for submitting high quality work.



RON DESANTIS
GOVERNOR

NATIONAL CANCER REGISTRARS WEEK IN FLORIDA

WHEREAS, cancer is one of the leading causes of death in Florida and the nation; and

WHEREAS, cancer registrars are health care professionals and data management experts that capture a complete history, diagnosis, treatment, and health status of every cancer patient in the United States, this compilation of data is fundamental to the nation's cancer prevention and treatment efforts; and

WHEREAS, the Florida Cancer Connect provides a centralized resource hub for cancer patients, caregivers, and families to help Floridians understand cancer research and gain access to prevention programs, health care providers, and other helpful resources; and

WHEREAS, in 2023, First Lady Casey DeSantis announced the Cancer Connect Collaborative, an expansion of Florida Cancer Connect that analyzes and rethinks Florida's approach to cancer by focusing on five primary goals to revolutionize Florida's approach to combatting cancer through data, best practices, innovation, funding, and honesty; and

WHEREAS, the data guides the work of oncologists, researchers, and public health officials to better monitor and advance cancer prevention and treatments, conduct research, improve cancer preventions and screening programs, and determine public health decisions; and

WHEREAS, the Framework for Freedom Budget for the 2023-24 fiscal year invests more than \$166 million in cancer research funding; and

WHEREAS, cancer registrars play an important role in the fight against cancer, and Florida appreciates their hard work and service to our families, friends, and loved ones; and

WHEREAS, National Cancer Registrars Week in Florida is an opportunity to recognize the essential role that cancer registrar professionals play in our healthcare system.

NOW, THEREFORE, I, Ron DeSantis, Governor of the State of Florida, do hereby extend greetings and best wishes to all observing April 3-7, 2023, as *National Cancer Registrars Week in Florida*.



IN WITNESS WHEREOF, I have hereunto set my hand and caused the Great Seal of the State of Florida to be affixed at Tallahassee, the Capitol, this 3rd day of April, in the year two thousand twenty-three.


Governor

THE CAPITOL
TALLAHASSEE, FLORIDA 32399 • (850) 717-9249

2022 Jean Byers Memorial Award

(2020 Cases)

FCDS has once again made the decision to cancel the 2022 Jean Byers Memorial Award for the 2020 data and instead give an Honorable Mention to those facilities that despite the many challenges were able to meet national data standards for timeliness and completeness in cancer reporting.

FCDS presents the Jean Byers Memorial Award for Excellence in Cancer Registration each year to those facilities that have met or exceeded the national quality standards for timeliness and completeness in cancer reporting. We recognize that the cancer registry community continues to encounter many challenges starting in 2018 and continuing through 2021, which has hindered many registries to meet many of the national quality benchmarks.

We would like to recognize the forty-three reporting facilities below because despite the many difficulties, they met or even exceeded the national quality standards for timeliness and completeness in cancer reporting. FCDS appreciates the commitment and effort that these facilities place in meeting these critical goals.

Criteria:

- Met the 2020 Annual Reporting Deadline of 6/30/21
- No more than 5% of the 2020 cancer case admissions reported to FCDS within 2 months (60 days) following the 6/30/21 deadline
- No more than 10% of the 2020 cancer case admissions reported to FCDS within 12 months following the 6/30/21 deadline

Honorable Mention

1306-ASCENSION SACRED HEART BAY

2379-LARKIN COMMUNITY HOSPITAL

1548-MELBOURNE REGIONAL MEDICAL CENTER

2606-SHANDS JACKSONVILLE MEDICAL CENTER

1686-FLORIDA MEDICAL CENTER

2647-NEMOURS CHILDREN'S HOSPITAL

1846-BAYFRONT HEALTH PUNTA GORDA

2672-WOLFSON CHILDREN'S HOSP

2146-NCH HEALTHCARE SYSTEM

2738-ASCENSION SACRED HEART

2306-HOMESTEAD HOSPITAL

3906-TAMPA GENERAL HOSPITAL

2307-WEST KENDALL BAPTIST HOSPITAL

3932-H LEE MOFFITT CANCER CENTER

2336-BAPTIST HOSPITAL MIAMI

3938-SOUTH FLORIDA BAPTIST HOSPITAL

2348-DOCTORS HOSPITAL

4516-LEESBURG REGIONAL MEDICAL CENTER

2349-HIALEAH HOSPITAL

4647-LEHIGH REGIONAL MEDICAL CENTER

2359-NICKLAUS CHILDREN'S HOSPITAL

5406-LOWER KEYS MEDICAL CENTER

2372-U OF MIAMI HOSPITAL CLINICS

5446-FISHERMENS HOSPITAL

2376-SOUTH MIAMI HOSPITAL

5471-MARINERS HOSPITAL

2377-WESTCHESTER GENERAL HOSPITAL

2378-CORAL GABLES HOSPITAL

(Continued on page 7)

(Continued from page 6)

5610-ASCENSION SACRED HEART EMERALD COAST 6349-WINTER HAVEN HOSPITAL
6003-DELRAY MEDICAL CENTER 6570-FLAGLER HOSPITAL
6068-WELLINGTON REGIONAL MEDICAL CENTER 6704-GULF BREEZE HOSPITAL
6246-JOHN HOPKINS ALL CHILDREN'S HOSPITAL 6707-SANTA ROSA MEDICAL CENTER
6305-LAKELAND REGIONAL MEDICAL CENTER 7005-VILLAGES REGIONAL HOSPITAL
6346-BARTOW REGIONAL MEDICAL CENTER

New Florida CTRs CONGRATULATIONS



Norma Caraballo-Bullard, Lutz
Jenica Cox, Palm Coast
Stephen Duggins, Deltona
Ernesto Garcia, Miami
Nereida Hansen, Kenneth City
Tricia LeFleur, Palm Harbor

Hannah Lord, Port Richey
Pamela McGhee, Cooper City
Eric Perdue, Pensacola
Susana Stiffler, Cooper City
Kathleen Wilson, Tallahassee
Teresa Woody, Leesburg

Earn the CTR


EXAM TESTING WINDOWS 2023

March 31 – April 22, 2023
Application Deadline: March 24

June 30 - July 22, 2023
Application Deadline: June 23

October 13 - November 4, 2023
Application Deadline: October 6

National Cancer Registrars Association
Council on Certification



Why are paraganglioma coded to C47.* Peripheral nerves/autonomic nervous system?

FCDS did not require reporting of paraganglioma for many years. Only in the past few years have SEER and NPCR recognized and began required reporting of these tumors. In the past Registrars would frequently report ‘glomus jugular tumors’ a type of head and neck paraganglioma, only to have them returned as ‘not reportable’. We even published articles to ‘not’ report them.

The 2002 passed federal Public Law 107 - 260 - Benign Brain Tumor Cancer Registries Amendment Act was created to start reporting benign and borderline tumors of the brain and central nervous system to cancer registries in the United States. However, it did not require reporting of neoplasms of the sympathetic, autonomic, or peripheral nerves unless they were malignant. Now some of these are reportable such as the paraganglioma of several anatomic locations which are neuroendocrine tumors. There was no change in the law, only a change in the interpretation and cancer reporting requirements.

FCDS now requires these tumors be reported beginning in 2021. The Solid Tumor Rules reflect this new requirement. However, they don’t give us a lot of information about these neoplasms...so here is more.

Most paraganglioma are benign nerve bundle tumors. They arise in the head and neck, abdomen and in the neck and mediastinum ones – 85% are abdominal, 12% mediastinal, only 3% are H&N.

Paraganglioma is a neuroendocrine tumor that grow from chromaffin cells – these cells are all over the place in the body but tend to bundle in a few specific locations. Their purpose is to help regulate blood pressure, blood sugar, heart rate among other things.


So the bundles, many of which are in the head & neck, communicate quickly with the CNS, circulatory system and solid organs to change blood pressure quickly and work with fight/flight responses (this is what neuroendocrine tumors and nerve bundles do – shortcuts to speed communications between organs or organ systems where they ‘live’ and the CNS to make for rapid response to certain stimuli).

Sometimes they are called extra-adrenal pheochromocytoma)...and they are pretty rare. They tend to bundle around the carotid artery (carotid body), outside the adrenal glands (pheochromocytoma), and the vagus nerve (one of the 12 cranial nerves) and in the larynx/chest. Most are benign. Up to 25% are malignant – only 10% of pheochromocytomas are malignant. They all (I think) secrete catecholamine.

Unlike some other tumors that we name by the organ in which they arise...these paraganglioma are to be coded to the C47.* series because they involve peripheral nerves and autonomic nervous system codes that most of us are not too familiar with. But they are tumors of the nervous system, not the blood circulation system or adrenal gland. That is why they get coded C47.*.

Updated FCDS Data Visualization Dashboard *now with 2020 Data*

The Florida Cancer Data System is pleased to announce updates to the Data Visualization Dashboard, which now includes 2020 data.



https://fcds.med.miami.edu/inc/statistics_data_viz.shtml

The Data Visualization Dashboard was developed to make statistics on the top cancers in Florida more accessible to the public. Statewide and county statistics are available for new cancers, cancer deaths and stage of disease. Statewide cancer trend data are available dating back to 2009.

How is this dashboard different from our other statistical dashboards? This dashboard contains helpful tips on the meaning of each statistic and is developed to be user friendly. It is an interactive tool that we hope will allow users to better understand what is happening with cancers in the state.

If you have any questions or comments you can contact Monique Hernandez, at FCDS for more information. Mhernandez5@med.miami.edu

FCRA/FCDS TASK FORCE

The FCRA/FCDS Task Force meets monthly to discuss issues related to Florida Cancer Registrars, Cancer Registry Standards and FCDS Operations relevant to registrars and registries across the state of Florida.

The Task Force includes representatives from large, small and corporate cancer registries, NCI designated cancer centers, software providers, interim service providers, registry contractors, radiation oncology centers, ambulatory surgery centers, FCDS and the FCRA Board of Directors. Most members wear multiple 'hats'.

The main purpose of the Task Force is to provide Florida registrars a means for communicating various issues for Cancer Registrars and the State Central Registry and to represent Florida Cancer Registrars relevant to FCDS Operations. The Task Force tackles problems such as issue resolution, improvement of reporting procedures with the hope of increasing efficiencies, software updates, problems with edits, FCDS Audits, FCSD and NAACCR Webinar Series', and to assist in identifying new areas of educational needs for our Florida Cancer Registry Community and areas worthy of revisiting. We work together to resolve problems statewide.

The Task Force's focus is currently working on the FCRA In-Person Annual Conference, the FCDS Virtual Annual Meeting and preparations for Florida's transition to NAACCRv23 Standards, 2023 Manuals and FCDS EDITSv23. Communication is a growing theme again to ensure consistency in interpreting manuals and instructions. We also spend time discussing FCDS Deadlines and FCDS' progress toward meeting national requirements to ensure Florida's cancer data is included in national statistics and national publications.

Future projects include developing a 'Florida Internship Sharing Program', and 'FCRA/FCDS Guide Hiring Contractors for Cancer Reporting in Florida', and continuation of problem solving as registries transition to the XML data transmission protocols and working through FCDS EDITS.

Questions and concerns can be submitted directly to the Task Force co-chairs; Marcia Hodge, FCRA President, and Steven Peace, FCDS Manager, at the click of a button on either the FCRA or FCDS Main Webpages.



Please submit questions and concerns to the Task Force co-chairs; Marcia Hodge, FCRA President, and Steven Peace, FCDS Manager, and we will add your topic to our monthly agenda for discussion.

Co-Chairs: Marcia Hodge (hodgem@shands.ufl.edu) and Steven Peace (speace@med.miami.edu)


Members: Cheryl Taft, Barbara Dearmon, Jennie Jones, Joyce Allan, Mayra Espino, Yolanda Topin, Lindsey Mason, Jesmarie Garcia, Gary Levin

SEER*Educate Training Module Releases

Winter 2023 Update

New Coding Practice Modules Diagnosis Years 2021-2023 (for Category A CEs)

We created additional site-specific “Mash-Up” coding modules to assess the coding accuracy for the Dx Year 2021-2023 changes to EOD, Summary Stage, Grade, and SSDI. Seven new sites (Larynx, Bone, GIST, Bile Ducts, Lip & Oral Cavity, Renal Pelvis & Ureter, Small Intestine) are included in the Winter Release. Release dates are indicated in the table below. All training modules for these cases qualify for Category A continuing education (CE) credits approved by NCRA. The number of CEs awarded is based on the average time it takes to code the cases and review the answers and the included rationales.




In addition to the release of these new primary site modules over the past four months, we are performing maintenance on all previously released primary site modules. The majority of the changes for the annual updates to Diagnosis Year 2023 Mash-Up training modules are allowed for use on cases diagnosed 2018 forward. The annual maintenance of the Dx 2021-2022 Mash-Ups involves switching the site-specific lookups from EOD V2.1 to EOD 3.0 and double-checking the rationales for updates to the code descriptions and notes for the various data items as well as the answers.

This Mash-Up maintenance work will extend through February. While we work on updating a few primary sites at a time, we disable only those tests for two to four days to complete the work. Then, we move the primary sites up the menu tree to the 2021-2023 EOD, Summary Stage, Grade, SSDI branch and reenable those sites for public use.

After we complete the Mash-Up maintenance, we will work on the Heme, Solid Tumor Rules, and Histology cases.

The number of free Category A CEs awarded for each training module completed is indicated in the table below. There is a total of 16 Category A CEs available in this release. The Program Recognition number to use when preparing your biannual CE submission is also provided to facilitate completing the NCRA documentation required to maintain your CTR credential.

NCRA Program Recognition #	Program Title Dx 2022-2023 EOD, Summary Stage, Grade, SSDI	Number of Cases	CE Ending Date	Category A CEs Approved	Date Released on SEER*Educate
2022-086	Larynx	5	12/31/2025	2.5	22-Nov
2022-083	Bone	5	12/31/2025	2.25	23-Dec
2022.084	GIST	5	12/31/2025	2.25	23-Dec
2022-085	Bile Ducts	5	12/31/2025	2.5	23-Jan
2022-087	Lip & Oral Cavity	5	12/31/2025	2.5	23-Jan
2022-088	Renal Pelvis & Ureter	5	12/31/2025	2.0	23-Jan
2022-045	Small Intestine	5	12/31/2025	2.0	23-Jan



SEER Program Coding and Staging Manual 2023

The 2023 SEER Program Coding and Staging Manual (SPCSM) includes data item descriptions, codes, and coding instructions for cases diagnosed on or after January 1, 2023. The manual explains the format and definitions of the data items required by SEER. For the benefit of experienced registrars looking for targeted training on the most recent changes, this training is divided into the following three topic areas with the first three to seven modules within each topic highlighting those most recent updates in the reportability rules, new data items, and coding changes or additions to the documentation:

- Reportability (first 6 modules)
- Tumor Description (first 3 modules)
- Treatment (first 7 modules)

To those sitting for the CTR exam looking for practice questions to test your knowledge of the material found in the Commission on Cancer (CoC) 2023 STAndards for Oncology Registry Entry (STORE) Manual, be aware that nearly all of the data items and definitions in the STORE Manual are also found in the SPCSM).

CoC Operative Standards 5.3 through 5.8

Additional practice questions are now available to assess one's understanding of the Operative Standards 5.3 through 5.8 outlined in the *2020 CoC Standards – Optimal Resources for Cancer Care*, which is one of the references for the 2023 CTR exam. These Standards outline the elements required for operative and pathology reports for selected primary sites.

These site-specific questions were developed to assess the registrars knowledge of the requirements involving compliance, implementation and synoptic reporting of these Standards.



Log in or sign up at SEER*Educate today by visiting <https://educate.fredhutch.org/> and **Learn by Doing!** These training modules are found in the following locations on this website:

- **Mash-Up** coding practice modules are under the **Training** tab, in **Coding - for CEs**
- **SEER Program Coding and Staging Manual 2023** is under the **Training** tab, in **CTR Prep - No CEs**
- **Operative Standards 5.3-5.8** is under the **Training** tab, in **CTR Prep - No CEs** under **Commission on Cancer (CoC)**

If you need help finding the exercises mentioned in this announcement, see the next few pages. If you have questions about accessing the exercises or printing the CE listing, please [Contact Us](#).

SEER*Educate is funded by Surveillance, Epidemiology and End Results (SEER) of the National Cancer Institute (NCI) and the Fred Hutchinson Cancer Center. (NCI Contract Number HHSN261201800004I)

Two-page instructions for those who need help accessing the coding training modules:

More about the Mash-Ups

We created a site-specific “mash-up” coding form to facilitate assessing coding accuracy for the Dx Year 2021-2023 changes to EOD, Summary Stage, Grade, and SSDI.


There is a case scenario (the “Click here” link) and we provide the read-only coding for site, histology, and behavior to ensure that the correct data items and drop-downs are retrieved from the SEER*RSA. These are the same drop-downs vendor software will display to registrars. However, the page that displays before the coding form provides links to the various relevant manuals which you should also have open and available to complete these exercises.

The screenshot shows a web interface titled "Coding Form". At the top, there is a blue header with a minus sign and the text "Coding Form". Below the header, a red arrow points to a link that says "Click here to open the case scenario required for the test in a new window." Below this, a red text block states: "These fields are read-only. The coding form needs them in order to retrieve the correct site specific lookups." followed by two numbered instructions: "1. New 2021 ICD-O-3.2 histology code/term updates have been made where applicable." and "2. Any changes to Solid Tumor Rules or Histology will not impact the use of these cases." Below the instructions are three dropdown menus: "Primary Site" with the value "C209", "Histology" with the value "8140", and "Behavior" with the value "3". A red arrow points to these three dropdowns with the text "Auto-populated by system". Below these are three sections of dropdown menus, each separated by a red horizontal line. The first section is titled "EOD and Summary Stage" and contains four dropdowns: "EOD Primary Tumor", "EOD Regional Nodes", "EOD Mets", and "Summary Stage 2018". The second section is titled "Grade" and contains four dropdowns: "Grade Clinical", "Grade Post Therapy Clin", "Grade Path", and "Grade Post Therapy Path". The third section is titled "Site-Specific Data Items (SSDI)" and contains a list of ten items, each with a dropdown menu: "CEA Pretreatment Lab Value", "CEA Pretreatment Interpretation", "Circumferential Resection Margin (CRM)", "KRAS", "Microsatellite Instability (MSI)", "Perineural Invasion", "Tumor Deposits", "BRAF Mutational Analysis", and "NRAS Mutational Analysis". At the bottom of the form, there are three buttons: "Score Now" (green), "Finish Later" (blue), and "Cancel" (red). A red arrow points to the "Score Now" button.


After you complete the coding form, click the Score Now button to compare your coding to the preferred answers and detailed rationales for each data item.

Quick reference on how to access new Dx Year 2021-2023 exercises and the CE report

To access the exercises, click on Training and then Coding – CEs to display the page with the test menu. Click on the + sign to expand the Dx 2021-2023 EOD line to display the sites.



To print a report demonstrating completion of the CEs, click on Reports Menu and then View Excel Reports.



Click on the + sign to expand CE Reports section and click on Dx Year 2021-2023 EOD, Summary Stage, Grade, SSDI row. Change the start date to a date prior to when you began this material, such as 12/1/2022 and change the end date to today's date.



If no results are returned, you may need to retake a specific exercise where you originally scored less than 70%. We recommend waiting at least two days before retaking an exercise so that you know you are testing your knowledge of what you learned from your first attempt versus your immediate short-term recall of reading the rationale.



2022-2023 Monthly NAACCR Cancer Surveillance Webinar Series

FCDS is pleased to offer another year of the Monthly NAACCR Cancer Registry and Surveillance Webinar Series - Free of Charge to Florida Registrars in Recorded Sessions.

This year in response to the Covid Pandemic, NAACCR provided FCDS with 42 'live attendance portals' for 42 lucky Florida Registrars to attend the 2021-2022 Webinar Series 'live'.

FCDS worked with our traditional 7 host sites to identify 6 registrars from each site-region who attended the NAACCR webinars routinely at their host site. These registrars were offered the 'live' attendance seats for Florida. Unfortunately, FCDS was unable to purchase 200-250 'live' attendee spots...but, we are fortunate to have acquired 42 slots for the 2021-2022 NAACCR Webinar Series.

For registrars who do not make the short list for the 'live' spots, FCDS offers every NAACCR Webinar as a 'recorded session' in FLccSC.

You can still earn 3 CEUs per webinar in FLccSC...just like we have for many years. Recordings appear in FLccSC within a week or two following the 'live' session.

And, old webinars can still be viewed – up to 2 years in arears. So, registrars can still gain 3 CEU credits for attendance at any NAACCR Webinar that is up to 2 years old.

The 2021-2022 NAACCR Webinar Series begins on October 7, 2021 and continues through September 1, 2022. The 2021-2022 Webinar Series Schedule is provided below.

DATE	TOPIC
* 10/6/21	Breast 2022 Part 1 Co-host: Wilson Apollo Part 1 of the Breast webinar will focus on treatment of breast cancer. We will discuss the new breast surgery codes, reconstruction, lymph node related data items, systemic treatment, and radiation.
* 11/3/21	Breast 2022 Part 2 Co-host: Denise Harrison Part 2 of the Breast webinar will focus on SSDIs and staging. Examples, quizzes, and case scenarios included.
* 12/1/21	Esophagus 2022 Co-host: Wilson Apollo This webinar will focus on anatomy, SSDIs, staging, and treatment with an emphasis on radiation. Examples, quizzes, and case scenarios included
* 1/12/23	Head and Neck 2023 Co-host: Vicki Hawhee This webinar will cover the anatomy, solid tumor rules, staging and treatment of Head & Neck cancers. Examples, quizzes, and case scenarios included.
* 2/2/23	Data Item Relationships Co-host: Jennifer Ruhl and Angela Costantini We will take an in-depth look at how codes for one data item impact codes for other data items. Examples, quizzes, and case scenarios included.
* 3/2/23	Boot Camp 2023 Guest Hosts: Nancy Etzold and Elaine Bomberger-Schmotzer This Boot Camp webinar will involve completing multiple quizzes with minimal lecture.
* 4/6/23	Prostate 2023 Co-host: Gillain Howell and Amy Bramburg This webinar will focus on the anatomy, SSDIs, staging, and treatment of prostate cancer. Examples, quizzes, and case scenarios included.
5/4/23	Lower GI 2023 Part 1 Co-host: Denise Harrison Part 1 of the Lower GI webinar will focus on colon, appendix, and anus. We will look at anatomy, solid tumor rules, and SSDIs for these sites. Examples, quizzes, and case scenarios included.
6/1/23	Lower GI 2023 Part 2 Co-host: Denise Harrison Part 2 of the Lower GI webinar we will discuss stage and treatment for colon, appendix, and anus. Examples, quizzes, and case scenarios included.
7/13/23	IT Worked for Me: In "FUN" matics in the Cancer Registry Co-host: Ronda Broome, Lisa Landvogt, Kelli Merriman This webinar features a variety of professional perspectives on how best to mix technology with data and utilizing the outcome to share relevant and valuable data analysis (informatics). This is THE next level for CTR's on the career ladder. We have spent decades on mastering the input of data, NOW is the time to take "IT" to the next level. Join us on our journey, "IT" is truly the fruit of our labor, from beginning to end.
8/3/23	Melanoma 2023 Co-host: Janine Smith We will look at solid tumor rules, staging, SSDIs, and new skin surgery codes for Melanoma. Examples, quizzes, and case scenarios included
9/7/23	Coding Pitfalls 2023 Co-host: Janet Vogel During this webinar we will review problematic coding issues identified through quality control of registry data

**CEU information
for the 2022 FCDS
Annual
Conference:**

CE Hours: 7.5

4 Hrs Category A

*NCRA Recognition
Number: 2022-127*



Florida Cancer Data System

Cancer Reporting Completeness Report



TOTAL NUMBER OF CASES IN THE FCDS MASTER FILE AS OF APRIL 30, 2023

Total number of *New Cases* added to the FCDS Master file in April, 2023 4,902

The figures shown below reflect initial patient encounters (admissions) for cancer by year.

ADMISSION YEAR	HOSPITAL	RADIATION	AMBI/SURG	DERMATOLOGY	PHYSICIANS CLAIMS	DCO	TOTAL CASES	NEW CASES	Tumors
2022	116,371	2,243	360	12,300	302	Pending	131,576	1,680	27,863
2021	225,654	6,472	464	12,272	21,502	Pending	266,364	2,730	124,029
2020	223,344	7,696	2,104	12,461	26,762	2,352	274,719	492	155,207
				<u>Actual</u>			<u>Expected</u>		
% Complete for:		2022	53%				83%	2022	21%
		2021	100%				100%	2021	95%
		2020	100%				100%	2020	100%

*Expected % based on 250,000 reported cases per year

Missed an FCDS or NAACCR Webinar?



Did you know that FCDS Webcasts and NAACCR Webinars can be viewed after-the -fact?

FCDS Webcasts and NAACCR Webinars are recorded and posted on the FCDS FLccSC LMS Site.

The FCDS Webcast recordings are available free of charge and can be viewed any-time/anywhere by anybody. NAACCR Webinars are restricted approved Florida FLccSC Users per FCDS/NAACCR agreement.

FCDS holds all FCDS/NAACCR recordings for 2 years before ‘retiring’ them due to outdated information.

Registrars must have an active Florida FLccSC Account and must take and pass the CEU Quiz as required to obtain some of the CEUs for certain FCDS Webcasts... always to obtain a Certificate of Attendance.

NAACCR Webinars have their own CEU award mechanism whether viewed live or via a recorded session.

Only Florida registrars with Active/Current FCDS Abstractor Codes can access the NAACCR Webinars.

Please contact FCDS for more information on viewing recorded webinars.

The Florida Cancer Data System (FCDS) is Florida's statewide, population-based cancer registry and has been collecting incidence data since 1981 when it was contracted by the State of Florida Department of Health in 1978 to design and implement the registry. The University of Miami Miller School of Medicine has been maintaining FCDS (<http://fcds.med.miami.edu>) since that time.

The FCDS is wholly supported by the State of Florida Department of Health, the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC) and the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

PROJECT DIRECTOR:

David Lee, PhD

DEPUTY PROJECT DIRECTOR:

Gary M. Levin, BA, CTR

EDITORS:

Gary M. Levin, BA, CTR
Steven Peace, BS, CTR
Melissa K. Williams

EDITOR ASSISTANT/ GRAPHICS DESIGNER:

Melissa K. Williams
Danielle Simmons

CONTRIBUTORS:

Steven Peace, BS, CTR
Megsyc C. Herna, BA, CTR

FCDS

PO Box 016960 (D4-11)
Miami, FL 33101

Phone: 305-243-4600
800-906-3034
Fax: 305-243-4871

<http://fcds.med.miami.edu>

